Gopi Shankar - 07 Feb 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Development Officer
Signature
By: /s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
07 Feb 2023
Net transactions value
$0
Form type
4
Filing time
09 Feb 2023, 16:06:58 UTC
Next filing
08 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 07 Feb 2023 Common Stock 180,000 $5.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 25% on February 7, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.